Stage IV Melanoma Clinical Trial
Official title:
Phase II Trial of 17-N-allylamino-17-demethoxy Geldanamycin (17-AAG, NSC #330507) Diluted in EPL Diluent (NSC #704057) in Metastatic Melanoma Patients
This phase II trial is studying how well tanespimycin works in treating patients with stage III or stage IV melanoma. Antitumor antibiotics such as tanespimycin may stop the growth of melanoma by stopping blood flow to the tumor.
Status | Terminated |
Enrollment | 50 |
Est. completion date | |
Est. primary completion date | February 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed melanoma - Stage III or IV disease - No primary melanoma of the choroid or mucosa - Measurable disease - At least 1 unidimensionally measurable lesion >= 20 mm by conventional techniques OR >= 10 mm by spiral CT scan - Tumor amenable to biopsy (for the first 10 patients in each stratum only) - Patients must have measurable disease in addition to the tumor(s) to be biopsied - No brain or epidural metastases - Completely resected solitary brain metastases allowed provided patient has been free of CNS metastases for >= 6 months - Performance status - Karnofsky 60-100% - Performance status - ECOG 0-2 - More than 3 months - Absolute neutrophil count >= 1,500/mm^3 - Platelet count >= 100,000/mm^3 - WBC >= 3,000/mm^3 - AST and ALT =< 2.5 times upper limit of normal - Creatinine normal - No symptomatic congestive heart failure - No unstable angina pectoris - No cardiac arrhythmia - No history of myocardial infarction - No history of prolonged QTc interval - No active ischemic heart disease within the past 12 months - No uncontrolled dysrhythmia or dysrhythmias requiring medication - No congenital prolonged QT syndrome - No left bundle branch block - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No prior allergic reaction attributed to compounds of similar chemical or biological composition to 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) - No prior serious allergic reaction to eggs - No other uncontrolled illness - No active or ongoing infection requiring systemic antimicrobial treatment - No psychiatric illness or social situation that would preclude study compliance - No more than 1 prior chemotherapy regimen for metastatic melanoma - Prior vaccines, cytokines, or interferon alfa is not considered prior therapy unless administered with a chemotherapy drug - More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered - Prior radiotherapy dose =< 3,000 cGy to fields including substantial marrow - More than 4 weeks since prior radiotherapy and recovered - No prior radiotherapy field that included the heart (e.g., mantle) - No concurrent combination antiretroviral therapy for HIV-positive patients - No concurrent medications that may prolong the QTc interval - No other concurrent anticancer therapy - No other concurrent investigational agents - No concurrent treatment with any of the following medications or herbal remedies: - Inhibitors of CYP3A4: - Fluconazole - Itraconazole - Ketoconazole - Macrolide antibiotics (azithromycin, clarithromycin, erythromycin, or troleandomycin) - Midazolam - Nifedipine - Verapamil - Diltiazem - Terfenadine - Cyclosporine - Cisapride - Inducers of CYP3A4: - Carbamazepine - Phenobarbital - Phenytoin - Rifampin - Herbal extracts and tinctures with CYP3A4 inhibitory activity: - Hydrastis canadensis (goldenseal) - Hypericum perforatum (St. John's wort) - Uncaria tomentosa (cat's claw) - Echinacea angustifolia roots - Trifolium pratense (wild cherry) - Matricaria chamomilla (chamomile) - Glycyrrhiza glabra (licorice) - Dillapiol - Hypericin - Naringin - No other concurrent herbal extracts |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Memorial Sloan-Kettering Cancer Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response rate (complete and partial response) | Up to 3 years | No | |
Secondary | Proportion of patients with stable disease | At 1 year | No | |
Secondary | Frequency of toxicities | Up to 3 years | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02107755 -
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Withdrawn |
NCT01216787 -
RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery
|
Phase 2 | |
Active, not recruiting |
NCT01026324 -
Dinaciclib in Treating Patients With Stage III-IV Melanoma
|
Phase 1/Phase 2 | |
Completed |
NCT01010984 -
LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma
|
N/A | |
Completed |
NCT00553306 -
Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma
|
Phase 1/Phase 2 | |
Completed |
NCT00121225 -
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
|
Phase 2 | |
Completed |
NCT00019448 -
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT03200847 -
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03235245 -
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib
|
Phase 2 | |
Terminated |
NCT01875653 -
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
|
Phase 3 | |
Completed |
NCT01748747 -
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
|
Early Phase 1 | |
Terminated |
NCT01316692 -
Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT01120275 -
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
|
Phase 2 | |
Terminated |
NCT01026051 -
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
|
Phase 2 | |
Terminated |
NCT01166126 -
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
|
Phase 2 | |
Terminated |
NCT01217411 -
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
|
Phase 1 | |
Completed |
NCT01037790 -
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
|
Phase 2 | |
Completed |
NCT00288041 -
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00074308 -
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT00072163 -
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
|
Phase 2 |